We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

77 hedge funds and large institutions have $195M invested in Adaptimmune Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more call options, than puts

Call options by funds: $219K | Put options by funds: $70K

0.44% more ownership

Funds ownership: 11.75% → 12.19% (+0.44%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 80 → 77 (-3)

15% less capital invested

Capital invested by funds: $229M → $195M (-$34.2M)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

30% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 23

Holders
77
Holders Change
-3
Holders Change %
-3.75%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
16
Reduced
23
Closed
15
Calls
$219K
Puts
$70K
Net Calls
+$149K
Net Calls Change
+$257K

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$11.6M
2
Bank of America
Bank of America
North Carolina
+$803K
3
ECM
ExodusPoint Capital Management
New York
+$515K
4
Barclays
Barclays
United Kingdom
+$434K
5
LFCM
Long Focus Capital Management
Puerto Rico
+$429K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.28M
2
Renaissance Technologies
Renaissance Technologies
New York
-$772K
3
ECM
Endurant Capital Management
California
-$579K
4
Rafferty Asset Management
Rafferty Asset Management
New York
-$548K
5
Two Sigma Investments
Two Sigma Investments
New York
-$544K
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
76
Eversept Partners
New York
– -$488K -237,086 Closed
Mitsubishi UFJ Asset Management
77
Mitsubishi UFJ Asset Management
Japan
– -$153K -74,256 Closed
GCP
78
GSA Capital Partners
United Kingdom
– -$143K -69,612 Closed
JF
79
Jump Financial
Illinois
– -$115K -55,600 Closed
IA
80
Inspire Advisors
Idaho
– -$93K -45,105 Closed
VEA
81
Virtus ETF Advisers
New York
– -$91K -44,300 Closed
II
82
Inspire Investing
Idaho
– -$66K -31,928 Closed
LWMG
83
Levy Wealth Management Group
Pennsylvania
– -$36K -17,590 Closed
HighTower Advisors
84
HighTower Advisors
Illinois
– -$31K -15,150 Closed
Squarepoint
85
Squarepoint
New York
– -$22K -10,800 Closed
PA
86
Parallel Advisors
California
– -$4K -1,853 Closed
ACM
87
Aquatic Capital Management
Illinois
– -$3K -1,600 Closed
SOW
88
State of Wyoming
Wyoming
– -$1K -635 Closed
CG
89
Cutler Group
California
– -$172 -100 -20%
HI
90
Harbour Investments
Wisconsin
– +$344 +200 New
1 2 3
4

ADAP Hedge Fund Activity: Q2 2022 in Review

77 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2022, worth a combined $195M — down 15% from $229M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ADAP and 12 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 16 added.

The largest buyer was PFM Health Sciences, adding an estimated $11.6M. The largest seller was Millennium Management, cutting an estimated $2.28M.

  • 77 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2022, down from 80 in Q1 2022.
  • Funds reported $195M of Adaptimmune Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
  • 12 funds opened new Adaptimmune Therapeutics positions in Q2 2022 and 15 closed out, a net change of -3 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2022 was PFM Health Sciences, an estimated $11.6M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2022 was Millennium Management, an estimated $2.28M sold.

Based on aggregated 13F filings for Q2 2022.